Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆
Megan Hames(Vanderbilt-Ingram Cancer Center), Leora Horn(Heidelberg University), Jonathan Aston(Vanderbilt-Ingram Cancer Center), Wade T. Iams(Vanderbilt University Medical Center), Christine M. Lovly(Dana-Farber Cancer Institute), Heidi Chen(Vanderbilt University Medical Center)
Cited by 66
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Mechanisms of receptor tyrosine kinase activation in cancer
|Molecular Cancer|2018|1.1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k